INmune Bio, Inc. (INMB)

The company's stock experienced a substantial decline of 82.23% from January 29, 2025, to January 28, 2026, and an 83.67% decrease over the last year. INmune Bio reported a net loss of $6.5 million in Q3 2025, an improvement from $12.1 million in Q3 2024, but the stock declined by 4.95% on the day the news was published. The Phase 2 MINDFuL trial for Alzheimer's disease missed its primary cognitive endpoints in the overall patient population, leading to management changes, including the retirement of CEO RJ Tesi and the appointment of David Moss as President & CEO, and Cory Ellspermann as Interim CFO. In December 2025, the company's price target was decreased by 37.50% to $5.36. In January 2026, INmune Bio provided an investor update on 2025 progress and future regulatory plans, and issued a shareholder letter reviewing 2025 milestones and outlining 2026 strategic initiatives.

As a clinical-stage biotechnology company, INmune Bio does not have commercialized products with traditional market demand seasonality. Its revenue is not driven by product sales but rather by funding, grants, and potential future licensing agreements or product approvals. The broader biotechnology sector can exhibit seasonality in investor sentiment, often influenced by the timing of regulatory decisions and major clinical trial announcements. Historical seasonality analysis suggests that January has historically favored a long bias, with the next statistically strong window culminating around February 25, 2026.

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies to reprogram the innate immune system for diseases like cancer and Alzheimer's. Their product platforms include DN-TNF, CORDStrom™, and INKmune®, with candidates like INKMUNE-Cancer, INB03-Cancer, XPRO1595, and LIVNate. The company focuses on precision therapy, matching drug mechanisms to patient biology and utilizing relevant outcome metrics in clinical development.

Headquartered in Boca Raton, Florida, INmune Bio extends its operational reach through its clinical trial activities. The company's Phase 2 Alzheimer's trial (AD02) is an international, multi-center study actively enrolling patients in Australia, Canada, and the United Kingdom. Regulatory approval for this trial is also anticipated in several European Union countries, including Poland.

INmune Bio's brand reputation has been impacted by mixed clinical trial results and a significant decline in stock price. The company currently holds a "Reduce" consensus rating from analysts. An AI-powered stock analysis model assigned INmune Bio an AI Score of 4/10, translating to a "Hold" rating, and indicated a lower probability of outperforming the market in the next three months. The mixed results from the Phase 2 Alzheimer's trial likely contributed to a negative perception, despite positive trends in a subgroup.

INmune Bio has a diverse ownership structure. Major institutional owners hold 5,376,340 shares across 140 institutional owners, including BlackRock, Inc., Vanguard Group Inc, and Geode Capital Management, Llc. Insiders hold 21.00% of the stock, with individuals and insiders collectively holding 17.01% of common stock.